European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Nanobiotix SA, Paris, France

Watch

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Dossier

The dossier is a printable PDF file, summarizing information and publications for this company. The creation of dossiers is included in your subscription. After the creation of the dossier is completed, it will be sent to your email address .

Add to dossier (if available):

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Name

Nanobiotix SA

Identification

Sirul
Siren 447521600
Stockp
NBTX
Stockp
NNBXF
Stockp
NANO.PA
Siret
Siret 44752160000034
Lei
969500667RSYIH8YL895
EUID
FR7501.447521600

Address

60 rue de Wattignies, 75012 Paris, France

Corporate purpose

2834
Pharmaceutical Preparations

The purpose of the Society is to: - research and development in the physical and natural sciences; - the filing, study, acquisition and granting of all patents, licences, processes, trademarks and the protection of specialised knowledge relating to or relating in any way to the fields or technologies falling within the scope of the company's purpose; - the design, development, manufacture, distribution, import, export and exploitation by any means of medicinal products, proprietary medicinal products, medical devices and other health goods; - the creation, acquisition, rental … Show more

Financials

Employees

For this company, Employees numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

History

Persons

Marketing & Tech

Network

Loading network
tax haven banner

Annual report

Publications

21 Jan 2026
Patent: Nanoparticles for Use AS Therapeutic Vaccine
30 Sept 2025
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
2 Apr 2025
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
31 Dec 2024
Balance sheet for 31/12/2024 · Earnings statement for 31/12/2024
9 Oct 2024
Patent: Nanoparticles for USE in Enhancing Brain Performances or in Treating Stress
18 Sept 2024
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
7 Aug 2024
Patent: Nanoparticles for USE for Treating a Neuronal Disorder
5 Jul 2024
Capital: €1,414,000
22 May 2024
Patent: Pharmaceutical Composition, Preparation and Uses Thereof
24 Apr 2024
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
13 Mar 2024
Capital: €1,414,000
31 Dec 2023
Balance sheet for 31/12/2023 · Earnings statement for 31/12/2023
11 Dec 2023
Patent: Novel Metal Oxide Nanoparticles and Compositions Thereof for USE AS Radioenhancers or for Visualizing Biological Tissue
31 Oct 2023
Capital: €1,056,911
31 Oct 2023
Capital: €1,085,701
26 Sept 2023
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
28 Jul 2023
Patent: Compositions OF nanoparticles for the treatment of neuropathic pain
28 Jul 2023
Patent: Compositions OF nanoparticles for the treatment of neuropathic pain
24 Apr 2023
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
31 Dec 2022
Balance sheet for 31/12/2022 · Earnings statement for 31/12/2022
28 Sept 2022
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
7 May 2022
Address · Legal form: SA à directoire (s.a.i.) · Name: NANOBIOTIX · Segment clas­si­fi­ca­tion
26 Apr 2022
Capital: €1,046,276
8 Apr 2022
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
31 Dec 2021
Balance sheet for 31/12/2021 · Earnings statement for 31/12/2021
Year 2021 in Epobase
4 European patent filings: Porous, High-Z and Carbon-Free Particles AS Radioenhancers …
8 Sept 2021
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
24 Aug 2021
Director: B. Van Rhijn · Chair of the Supervisory Board: Gary Phillips · No longer Director: Philippe Mauberna · No longer Chair of the Supervisory Board: Laurent Condomine · Capital: €1,044,776
13 Aug 2021
Director: B. van Rhijn · No longer President: Laurent Condomine · No longer Director: Philippe Mauberna
13 Aug 2021
Capital: €1,032,964
13 Aug 2021
Capital: €1,044,776
5 May 2021
Annual report for the year ending 31/12/2020 · Balance sheet for 31/12/2020 · Earnings statement for 31/12/2020
5 May 2021
Consolidated Annual report for the year ending 31/12/2020 · Balance sheet for 31/12/2020 · Earnings statement for 31/12/2019
8 Apr 2021
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
7 Apr 2021
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
31 Dec 2020
Balance sheet for 31/12/2020 · Earnings statement for 31/12/2020
12 Nov 2020
Capital: €781,114
6 Nov 2020
Capital: €780,934
14 Oct 2020
Patent: Metallic Nanoparticles, Preparation and Uses Thereof
7 Jun 2020
Capital: €681,934
26 May 2020
Consolidated Annual report for the year ending 31/12/2019 · Balance sheet for 31/12/2019 · Earnings statement for 31/12/2018
26 May 2020
Annual report for the year ending 31/12/2019 · Balance sheet for 31/12/2019 · Earnings statement for 31/12/2019
10 May 2020
No longer Director (1) · Capital: €672,451
31 Dec 2019
Balance sheet for 31/12/2019 · Earnings statement for 31/12/2019
24 Sept 2019
Capital: €672,451
22 Sept 2019
Director (2) · Capital: €670,801
15 Sept 2019
No longer Director (2) · Capital: €670,801
12 Sept 2019
Director (2)
5 Sept 2019
Director (2)
19 Jun 2019
Patent: Compositions Comprising Nanoparticles of Hafnium (IV) Oxide or Rhenium (IV) Oxide in Combination with Ionizing Radiations for Treating Cancer
4 Jun 2019
Capital: €670,801
31 May 2019
Capital: €666,001
14 May 2019
Annual report for the year ending 31/12/2018 · Balance sheet for 31/12/2018 · Earnings statement for 31/12/2018
14 May 2019
Annual report for the year ending 31/12/2018 · Balance sheet for 31/12/2018 · Earnings statement for 31/12/2018
14 May 2019
Consolidated Annual report for the year ending 31/12/2018 · Balance sheet for 31/12/2018 · Earnings statement for 31/12/2017
17 Apr 2019
Patent: Compositions for USE in Oncology
20 Mar 2019
Patent: Nanoparticles Comprising Metallic and Hafnium Oxide Materials, Preparation and Uses Thereof
31 Dec 2018
Balance sheet for 31/12/2018 · Earnings statement for 31/12/2018
Year 2018 in Epobase
5 European patent filings: Nanoparticles for USE for Treating a Neuronal Disorder …
26 Oct 2018
Pres.: Laurent Condomine, Laurent S. J. Levy · SB: Alain Herrera, Anne-Marie Salaün, Ralph Enno Spillner · VP: Anne-Marie Salaün · Director (3) …
30 Jun 2018
No longer Auditor: Auditex · Capital: €589,001
21 Jun 2018
Consolidated Annual report for the year ending 31/12/2017 · Balance sheet for 31/12/2017 · Earnings statement for 31/12/2016
21 Jun 2018
Annual report for the year ending 31/12/2017 · Balance sheet for 31/12/2017 · Earnings statement for 31/12/2017
21 Jun 2018
No longer Auditor: Auditex SAS
30 Apr 2018
Member of the Supervisory Board: Christophe Douat · Auditor: Grant Thornton · No longer Auditor (2 companies) · Capital: €526,854
30 Apr 2018
Vice president: Anne-Marie Graffin · No longer Member of the Supervisory Board: Christophe Douat · Capital: €526,854
30 Apr 2018
Capital: €530,748
30 Apr 2018
Capital: €589,001
19 Apr 2018
Member of the Supervisory Board: Christophe Douat · Auditor: Ernst & Young et Autres SAS à capital variable, Grant Thornton SA · No longer Auditor (2 companies)
25 Jan 2018 via Nanobiotix Spain SL
Proprietor: Nanobiotix Spain SL
2 Jan 2018
Consolidated Annual report for the year ending 31/12/2016 · Balance sheet for 31/12/2016 · Earnings statement for 31/12/2015
2 Jan 2018
Annual report for the year ending 31/12/2016 · Balance sheet for 31/12/2016 · Earnings statement for 31/12/2016
31 Dec 2017
Balance sheet for 31/12/2017 · Earnings statement for 31/12/2017
Year 2017 in Epobase
4 European patent filings: Nanoparticles for USE for Enhancing Brain Performances or for Treating Stress …
10 Aug 2017 in Hor
EU funding: Mobilising the European nano-biomedical ecosystem
2 Jun 2017
Capital: €526,854
28 Feb 2017
Capital: €478,958
16 Feb 2017
President: Laurent Condomine, Laurent S. J. Levy · Vice president: Christophe Douat · Member of the Supervisory Board (4) · Director (3) · Auditor (4 companies)
31 Dec 2016
Balance sheet for 31/12/2016 · Earnings statement for 31/12/2016
7 Sept 2016
Patent: Inorganic Nanoparticles of High Density to Destroy Cells in-Vivo
26 Aug 2016
Capital: €469,061
10 Aug 2016
Patent: Method of Monitoring the Release From Liposomes of a Product of Interest Using Superparamagnetic Nanoparticles.
28 Apr 2016
Capital: €467,561
14 Apr 2016
Capital: €424,973
31 Dec 2015
Balance sheet for 31/12/2015 · Earnings statement for 31/12/2015
24 Nov 2015
Patent: Pharmaceutical Composition, Preparation and Uses Thereof
24 Nov 2015
Patent: Pharmaceutical Composition, Preparation and Uses Thereof
13 Oct 2015
Capital: €421,943
13 Oct 2015
Capital: €424,883
14 Apr 2015
Capital: €421,883
1 Jan 2015 in Hor
EU funding (€408,250): Enabling NAnomedicine TRANSlation
31 Dec 2014
Balance sheet for 31/12/2014 · Earnings statement for 31/12/2014
Year 2014 in Dpmap
11 patent filings: Zusammensetzungen zur Verwendung in der Onkologie …
19 Dec 2014
Patent: Pharmaceutical Composition Comprising Nanoparticles, Preparation and Uses Thereof
27 Jul 2014
Member of the Supervisory Board: Ralph Spillner · Capital: €402,383
24 Apr 2014
Capital: €402,383
27 Mar 2014
Member of the Supervisory Board: Alain Herrera · No longer Member of the Supervisory Board (1) · Capital: €322,572
27 Mar 2014
Member of the Supervisory Board: Christophe Douat · Vice president: Christophe Douat · Capital: €322,572
27 Mar 2014
Director: Philippe Mauberna · Capital: €322,572
27 Mar 2014
Member of the Supervisory Board: Anne-Marie Graffin · Capital: €322,572
27 Mar 2014
No longer Member of the Supervisory Board: Seventure Partners · Capital: €322,572
27 Mar 2014
No longer Member of the Supervisory Board: CAP Decisif Management · Capital: €322,572
27 Mar 2014
Capital: €322,872
31 Dec 2013
Balance sheet for 31/12/2013 · Earnings statement for 31/12/2013
20 Dec 2013
Patent: Pharmaceutical Composition Comprising Nanoparticles, Preparation and Uses Thereof
10 Jul 2013
No longer Director-General (1) · Capital: €322,572
10 Jul 2013
No longer Member of the Supervisory Board: Amorcage Rhone Alpes · Capital: €322,572
10 Jul 2013
No longer Member of the Supervisory Board: CM-CIC Capital Innovation · Capital: €322,572
1 Mar 2013
Capital: €322,572
11 Jan 2013
Member of the Supervisory Board: Seventure Partners · No longer Member of the Supervisory Board: Masseran Gestion · Capital: €319,964
31 Dec 2012
Balance sheet for 31/12/2012 · Earnings statement for 31/12/2012
29 Nov 2012
Capital: €319,964
1 Sept 2012 in Fts
EU funding (€17,063.67): Enabling the European Nanomedicine Area Until 2020
9 Aug 2012
Patent: Nanopartikelabgabesysteme, Herstellung und Verwendungen Davon
9 Aug 2012
Patent: Nanopartikelabgabesysteme, Herstellung und Verwendungen Davon
9 Aug 2012
Patent: Verfahren zur Überwachung der Freisetzung von Liposomen AUS Einem Produkt von Interesse Mithilfe Superparamagnetischer Nanopartikel
13 Jul 2012
Member of the Supervisory Board: Isabelle Bou Antoun, Isabelle Miquel · Director (1) · SB: Amorcage Rhone Alpes, Amorcage Rhone Alpes SAS, CM-CIC Capital Innovation · Capital: €241,031
13 Jul 2012
Member of the Supervisory Board: Jérôme Snollaerts · Member of the Supervisory Board: CAP Decisif Management · No longer Member of the Supervisory Board: CAP Decisif (SAS) · Capital: €241,616
11 May 2012
Auditor: Auditex, Ernst & Young et Autres · Capital: €241,031
4 Jan 2012
Member of the Supervisory Board: Laurent Condomine, Christophe Douat · No longer Chair SB (1) · No longer SB: Matignon Investissement et Gestion, OTC Asset Management · Capital: €230,321
4 Jan 2012
Chair of the Supervisory Board: Laurent Condomine · No longer Member of the Supervisory Board (1) · Capital: €230,321
31 Dec 2011
Balance sheet for 31/12/2011 · Earnings statement for 31/12/2011
26 Oct 2011
Patent: Magnetic Nanoparticles Compositions and Uses Thereof
3 Sept 2010 as Nanobiotix SA à directoire et conseil de surveillance
SB: Sébastien Groyer, Karine Lignel, Aurélie Wirotius · No longer Auditor (1) · SB: Amorcage Rhone Alpes, Masseran Gestion, Vizille Capital Innovation · Auditor: Audit Finance de la Tour …
3 Sept 2010 as Nanobiotix SA à directoire et conseil de surveillance
Capital: €230,321
26 Aug 2010 as Nanobiotix SA à directoire et conseil de surveillance
Capital: €141,933
26 Aug 2010 as Nanobiotix SA à directoire et conseil de surveillance
Capital: €229,604
2 Jul 2010 as Nanobiotix SA à directoire et conseil de surveillance
Capital: €111,065
1 Nov 2009 as Nanobiotix SA à directoire et conseil de surveillance
Capital: €110,403
10 Jul 2009
Patent: Metallic Nanoparticles, Preparation and Uses Thereof
4 Jun 2009
Patent: Inorganic Nanoparticles, Preparation and Uses Thereof
11 Feb 2009 as Nanobiotix SA à directoire et conseil de surveillance
Capital: €109,353
4 Nov 2008 as Nanobiotix SA à directoire et conseil de surveillance
No longer Member of the Supervisory Board (2) · Capital: €108,853
2 Sept 2008 as Nanobiotix SA à directoire et conseil de surveillance
Director (1) · Capital: €96,298
2 Sept 2008 as Nanobiotix SA à directoire et conseil de surveillance
Capital: €108,853
6 Aug 2008
Patent: X-RAY and/or UV Activatable Particles, Their Preparation and Their Therapeutic or Diagnostic Uses
5 Jun 2008
Patent: Inorganic Nanoparticles of High Density to Destroy Cells in-Vivo
1 Jan 2008
Segment clas­si­fi­ca­tion
3 May 2007
Address
19 Apr 2006
Patent: Magnetic Nanoparticles Compositions and Uses Thereof
4 Nov 2005
Patent: Nanoparticles Comprising an Intracellular Targeting Element and Preparation and USE Thereof
29 Mar 2005
Address
25 Dec 2004
Legal form: SA à directoire (s.a.i.)
1 Mar 2003 as Nanobiotix Sàrl
Legal form: Société à responsabilité limitée (sans autre indication) · Name: NANOBIOTIX
There are no publications matching your search.

Mentions

19 Oct 2024 in Rne
Reg­is­tra­tion: 01/03/2003 · Pres.: Laurent S. J. Levy · Director: Anne Guicherd-Callin, B. van Rhijn · SB: Alain Herrera, Ralph Enno Spillner · VP: Anne-Marie Salaün · Capital: €1,414,000 …
11 Oct 2017 in Hrdk
Nanobiotix Germany GmbH: “Liste der Gesellschafter“
There are no publications matching your search.

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Creative Commons License The visualizations for "Nanobiotix SA, Paris, France" are provided by North Data and may be reused under the terms of the Creative Commons CC-BY license.

Printing is only available to North Data premium service subscribers.